Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) – Analysts at Jefferies Financial Group cut their FY2022 EPS estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, May 3rd. Jefferies Financial Group analyst M. Yee now expects that the biopharmaceutical company will post earnings of ($3.70) per share for the year, down from their prior forecast of ($3.68). Jefferies Financial Group also issued estimates for Esperion Therapeutics’ Q1 2023 earnings at ($0.71) EPS, Q4 2023 earnings at ($0.65) EPS and FY2023 earnings at ($2.72) EPS.
A number of other equities analysts have also recently issued reports on the company. HC Wainwright began coverage on Esperion Therapeutics in a report on Thursday, March 10th. They set a “buy” rating and a $22.00 target price on the stock. JPMorgan Chase & Co. upgraded Esperion Therapeutics from an “underweight” rating to a “neutral” rating and set a $6.00 price objective on the stock in a report on Wednesday. Credit Suisse Group cut their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a “neutral” rating on the stock in a report on Friday, January 14th. StockNews.com assumed coverage on Esperion Therapeutics in a report on Thursday, March 31st. They set a “sell” rating on the stock. Finally, Northland Securities cut their price objective on Esperion Therapeutics from $10.00 to $5.00 in a report on Wednesday, January 12th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Esperion Therapeutics has a consensus rating of “Hold” and an average target price of $21.00.
Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last issued its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.11. The company had revenue of $18.84 million for the quarter, compared to the consensus estimate of $15.41 million. During the same quarter last year, the business posted ($3.50) EPS. Esperion Therapeutics’s quarterly revenue was up 136.1% on a year-over-year basis.
Several large investors have recently bought and sold shares of ESPR. Marshall Wace LLP acquired a new position in shares of Esperion Therapeutics during the 1st quarter worth approximately $186,000. Royal Bank of Canada increased its holdings in shares of Esperion Therapeutics by 70.1% during the 2nd quarter. Royal Bank of Canada now owns 6,550 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 2,699 shares during the last quarter. Invesco Ltd. acquired a new position in shares of Esperion Therapeutics during the 2nd quarter worth approximately $225,000. Wells Fargo & Company MN increased its holdings in shares of Esperion Therapeutics by 160.9% during the 2nd quarter. Wells Fargo & Company MN now owns 26,990 shares of the biopharmaceutical company’s stock worth $572,000 after acquiring an additional 16,644 shares during the last quarter. Finally, Morgan Stanley increased its holdings in shares of Esperion Therapeutics by 258.9% during the 2nd quarter. Morgan Stanley now owns 386,515 shares of the biopharmaceutical company’s stock worth $8,175,000 after acquiring an additional 278,813 shares during the last quarter.
Esperion Therapeutics Company Profile (Get Rating)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
- Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Peak Growth Is Over For Etsy
- Uber Fails To Impress
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.